ngµç×ÓÓÎÏ·

05

¿ÆÑÐÏ£Íû

³Ì·¼¡¢¡¢³Âºì²¨ÍŶÓʹÓÃÒÅ´«ÎÄ¿â¸ßͨÁ¿É¸Ñ¡ÊÖÒÕÔÚÖ×Áö¾«×¼ÖÎÁÆÑо¿ÁìÓòÈ¡µÃϵÁÐÐÂЧ¹û

¸å¼þȪԴ£º£ºÒ©Ñ§Ôº£¨ÉîÛÚ£© ±à¼­£º£ºÎâÁ¢¼á ÉóºË£º£ºËïÒ«±ó ÔĶÁÁ¿£º£º

ngµç×ÓÓÎÏ·ÐÂÎÅÍøÑ¶£¨Í¨Ñ¶Ô±³Ì·¼£©½üÆÚ£¬£¬£¬ngµç×ÓÓÎϷҩѧԺ£¨ÉîÛÚ£©µÄ³Ì·¼¡¢¡¢³Âºì²¨½ÌÊÚÍŶÓʹÓÃCRISPR/Cas9ÒÅ´«ÎÄ¿âɸѡƽ̨·¢Ã÷Ö×Áöϸ°ûµ÷ÀíÄÚÔ´ÐÔPD-L1±í´ïµÄÒ»ÌõÐÂͨ·£¬£¬£¬ÎªÖ×ÁöÃâÒßÖÎÁÆÌṩÁËÒ»¸öDZÁ¦°ÐµãTRAF6£¬£¬£¬²¢ÑéÖ¤Á˸ðеãµÄÒÖÖÆ¼ÁÅðÌæ×ôÃ×¶Ô¶ñÐÔÐþÉ«ËØÁöµÄÖÎÁÆÇ±Á¦¡£¸ÃÑо¿»ùÓÚÍŶӽ¨ÉèµÄÓ¦¼¤ÓëÂѰ×ÎÈ̬CRISPR/Cas9ÎÄ¿â¸ßͨÁ¿É¸Ñ¡ÎĿ⣬£¬£¬Á¬ÏµTMT-¶¨Á¿ÂѰ××éѧЧ¹û£¬£¬£¬ÓëÁÙ´²ÑùÆ·Êý¾Ý¾ÙÐн»»¥ÆÊÎö£¬£¬£¬É¸Ñ¡²¢È·¶¨E3·ºËØÅþÁ¬Ã¸TRAF6ÊÇPD-L1µÄÒªº¦ÉÏÓε÷ÀíÒò×Ó£¬£¬£¬²¢ÆÊÎöTRAF6ͨ¹ýK63¶à¾Û·ºËØ»¯ÐÞÊÎÐÂλµãYAP1K497£¬£¬£¬ÔöÇ¿YAP1µÄÎȹÌÐÔ£¬£¬£¬Ôö½øYAP1µÄÉó¶¨Î»£¬£¬£¬²¢Ìá¸ßYAP1/TFCP2¸´ºÏÎï¶ÔPD-L1ת¼ÔöÇ¿×÷Óá£Í¬Ê±£¬£¬£¬¸ÃÑо¿ÑéÖ¤ÁËTRAF6ÒÖÖÆ¼ÁÅðÌæ×ôÃ×£¨Bortezomib£©¶Ô¶ñÐÔÐþÉ«ËØÁö·Î×ªÒÆµÄÖÎÁÆ×÷Óü°¶ÔÖ×Áö½þÈóÃâÒßϸ°ûµÄ¼¤»î×÷Óá£ÌØÊâµØ£¬£¬£¬ÅðÌæ×ôÃ×ÔöÇ¿¿¹Ö×ÁöÃâÒߵij̶È£¬£¬£¬ÄÜÓëPD-1µ¥¿Ë¡¿¹ÌåÁÆ·¨ÏàæÇÃÀ£¬£¬£¬ÇÒ¹ØÓÚСÊóÁÜͶºÏ¡¢¡¢Æ¢ÔàµÄÃâÒß¹¦Ð§ÎÞÏÔן±×÷Óᣱ¾Ñо¿¿ªÍØÁËÁÙ´²ÖÎÁƶ෢ÐÔ¹ÇËèÁöµÄÒ»Ïß°ÐÏòÒ©ÎïÅðÌæ×ôÃ×µÄÐÂÓ¦Óó¡¾°£¬£¬£¬ÊµÏÖ¸ÃÒ©ÎïµÄ¡°ÀÏÒ©ÐÂÓᱡ£

ngµç×ÓÓÎϷҩѧԺ£¨ÉîÛÚ£©²©Ê¿Ñо¿ÉúÍõÁèè´ºÍ2018¼¶Ë¶Ê¿Ñо¿ÉúÁõÏþÑàΪÕâÏîÑо¿µÄÅäºÏµÚÒ»×÷Õߣ¬£¬£¬³Ì·¼½ÌÊÚ¡¢¡¢³Âºì²¨½ÌÊÚ¼°½­ËÕ´óѧÁ¥ÊôÒ½ÔºÖ캣ÌνÌÊÚΪÅäºÏͨѶ×÷Õß (Cancer Letters, 2024, IF=9.2£¬£¬£¬ÖпÆÔº1Çø£©¡£¸ÃÊÂÇé»ñµÃÁ˹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ð¡¢¡¢¹ã¶«Ê¡¹ú¼Ê¿Æ¼¼ÏàÖúÏîÄ¿ºÍ¹ã¶«Ê¡Ïû»¯ÏµÍ³¶ñÐÔÖ×Áö·ÀÖÎÑо¿ÖصãʵÑéÊҵȶà¸öÏîÄ¿µÄÖ§³Ö¡£

4436CCFFDD3E7218BAD4DE11A9B_7B1869D3_49A6A

TRAF6/YAP1-TFCP2/PD-L1×÷ÓûúÖÆÍ¼

ͬʱ£¬£¬£¬½üÆÚ¸ÃÍŶӻ¹»ùÓÚCRISPR/Cas9¸ßͨÁ¿´úлÎÄ¿âɸѡÊÖÒÕÆ½Ì¨ºÍPDXÄ£×Ó£¬£¬£¬·¢Ã÷Ö§Á´°±»ùËá×ªÒÆÃ¸2£¨BCAT2£©µ÷¿ØÖ×Áöϸ°ûÌúéæÃü·´¿¹µÄ»úÖÆ£¬£¬£¬¼´Ìú×ÔÊÉ-AMPK-SREBP1;¾¶ÔöÇ¿BCAT2ת¼ºÍø»îÐÔ£¬£¬£¬Ôö½øÄÚÔ´ÐԹȰ±ËáºÏ³ÉÔöÌí£¬£¬£¬½µµÍÖ¬ÖʹýÑõ»¯Ë®Æ½£¬£¬£¬ÒýÆð¸Î°©ºÍÒÈÏÙ°©ÌúéæÃü·´¿¹£¬£¬£¬²¢ÍØÕ¹Á˳¦µÀ¡°ÀÏÒ©¡±Áøµª»Çà×वÄÐÂÓÃ;£¬£¬£¬·¢Ã÷ÆäÁªºÏË÷À­·ÇÄᣬ£¬£¬ÒÖÖÆÖ×ÁöÖÐBCAT2±í´ï£¬£¬£¬²¢ÏÔÖøÌáÉý¶ÔÄÍÒ©ÄÑÖÎÐԸΰ©ºÍÒÈÏÙ°©µÄÖÎÁÆÐ§¹û (Cell Death and Differentiation, 2021, IF=13.7£¬£¬£¬ÖпÆÔº1Çø£©¡£ÍŶӻ¹Éè¼ÆÁ˰ÐÏò¸Î°©ÌúéæÃüµÄÍâÃÚÌåÑùÄÒÅÝÐÞÊÎÕ½ÂÔ£¬£¬£¬½«ÉøÍ¸µÄתÌúÂѰ×ͨ¹ýÒ»¸ö궨ÐòÁÐÀο¿±í´ïÔÚĤÉÏ£¬£¬£¬ÖƱ¸³ÉÄÉÃ×ÄÒÅÝ£¬£¬£¬°üÔØÌúéæÃüÓÕµ¼¼ÁË÷À­·ÇÄᣬ£¬£¬Í¨¹ýĤÉϵÄתÌúÂѰ×ÊÜÌå½éµ¼µÄÄÚÍÌ×÷ÓýøÈë¸Î°©Ï¸°û£¬£¬£¬±»ÁѽâºóÊͷųöË÷À­·ÆÄáºÍÖ¬ÖʺϳÉÖÊÁÏÌúÀë×Ó£¬£¬£¬Ð­Í¬¼ÓËÙÖ¬ÖʹýÑõ»¯ÎïµÄ»ýÀÛ£¬£¬£¬µ¼ÖÂÌúéæÃü¡£ÌåÍâºÍÌåÄÚʵÑ鶼֤ʵ£¬£¬£¬´ËÕ½ÂÔÄÜÀÖ³ÉÓÕµ¼¸Î°©Ï¸°ûÌúéæÃü£¬£¬£¬²¢ÇÒÏÔÖøÒÖÖÆÆ¤ÏÂÁöºÍԭλ¸Î°©Éú³¤ (Biomaterials Research, 2023, IF=15.8£©¡£¸ÃÊÂÇé»ñµÃ2023Äê¶È½­ËÕÊ¡¿ÆÑ§ÊÖÒÕ½±ÈýµÈ½±¡£

ÏÖÔÚÁÙ´²ÉÏÖ÷ҪʹÓø߼ÁÁ¿°¢ÌǰûÜÕÖÎÁƸ´¾ÙÊÂÖÎÐÔ°×Ѫ²¡£¬£¬£¬È»¶øÐí¶à»¼ÕßÓÉÓÚ¸±×÷Óöø·ÅÆúÖÎÁÆ¡£ÎªÁËÅжϵͼÁÁ¿°¢ÌǰûÜÕÁªºÏÖÂËÀ°Ðµã£¬£¬£¬±¾ÍŶÓÁªºÏÇ廪´óѧºÍÄÏ·½Ò½¿Æ´óѧÖ齭ҽԺѪҺ¿ÆÊ¹ÓÃCRISPR/gRNAÒÅ´«ÎÄ¿âÊÖÒÕ¾ÙÐÐÁËɸѡ£¬£¬£¬²¢Åжϵ½PHF6ÊÇÒªº¦ÁªºÏÖÂËÀ°Ðµã¡£PHF6 Í»±ä¼ûÓÚ16%µÄ¶ùͯºÍ38%µÄ³ÉÈËT-ALL»¼Õߣ¬£¬£¬È»¶ø»¹Ã»ÓÐÕë¶ÔPHF6Í»±äÐͰ×Ѫ²¡µÄ¾«×¼ÖÎÁÆ·½°¸¡£Ê×ÏÈͨ¹ýÁÙ´²»ØÊ×ÐÔÊӲ죬£¬£¬·¢Ã÷PHF6Í»±äµÄ°×Ѫ²¡»¼Õß¶Ô°¢ÌǰûÜյȳ£Óû¯ÁÆÒ©ÎïÄÍÒ©£¨Cancer Med. 2022 Sep 29. doi:10.1002/cam4.5173£©¡£½øÒ»²½ÍŶÓÕ¹ÏÖPHF6ÊÇÒ»ÖÖÖ÷ÒªµÄ×éÂѰ׼׻ù»¯(ÐÞÊÎ)ÃÜÂë½â¶ÁÆ÷£¬£¬£¬¿ÉÒÔʶ±ðºÍÁ¬ÏµºËÈÊÇøÓòȾɫÖÊ×éÂѰ×ÉϵÄH3K9me3ºÍH3K27me1£¬£¬£¬²¢½«×éÂѰ׼׻ù×ªÒÆÃ¸SUV39H1ÕÐļµ½ºËÈÊÖУ¬£¬£¬Î¬³ÖºËÈÊrDNA»ùÒò×ùλȾɫÖʵÄÒìȾɫÖÊ״̬£¬£¬£¬´Ó¶øÒÖÖÆrDNA»ùÒòµÄת¼ºÍºËÌÇÌåµÄ×é×°¡£PHF6ÁÙ´²Í»±äÌåµÄºËÈʶ¨Î»£¬£¬£¬Ê¶±ðºÍÁ¬ÏµH3K9me3£¬£¬£¬ÒÔ¼°ÕÐļSUV39H1µÄÄÜÁ¦½µµÍ£¬£¬£¬µ¼ÖÂrDNAת¼»îÐÔÔöÌí¡¢¡¢ÌåÍâ°×Ѫ²¡Ï¸°ûÔöÖ³ºÍÌåÄÚСÊó°×Ѫ²¡ÒìÖÖÒÆÖ²ÎïÉú³¤¡£¸üÖ÷ÒªµÄÊÇ£¬£¬£¬ÔÚPHF6Í»±äµÄÁÙ´²AML»¼ÕßÑù±¾ÖÐÒ²ÊӲ쵽rRNAǰÌå·Ö×ӵıí´ïˮƽÏÔÖøÉý¸ß£¬£¬£¬½øÒ»²½Ö¤ÊµÎúÌåÍâÑо¿Ð§¹û¡£½øÒ»²½£¬£¬£¬·¢Ã÷Ò»¸örDNAÌØÒìÐÔת¼ÒÖÖÆ¼ÁCX5461Äܹ»ÏÔÖø½µµÍPHF6¹¦Ð§È±Ê§µÄU937 AMLϸ°û¶Ô°¢ÌǰûÜÕµÄÄÍÒ©ÐÔ¡£´ËÑо¿½ÒÏþÔÚActa Pharmaceutica Sinica B£¬£¬£¬2022£¬£¬£¬IF=14.5£¬£¬£¬ÖпÆÔº1Çø¡£¸ÃÊÂÇé»ñµÃÁ˹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ð¡¢¡¢¹ã¶«Ê¡×ÔÈ»¿ÆÑ§»ù½ðºÍÉîÛÚÊÐѧ¿Æ½á¹¹ÏîÄ¿µÄ×ÊÖú¡£

±ðµÄ£¬£¬£¬±¾ÍŶÓÒÀÍÐngµç×ÓÓÎϷҩѧԺ£¨ÉîÛÚ£©£¬£¬£¬»¹Àֳɽ¨ÉèÁ˹æÄ£»¯ÍâÃÚÌå/ϸ°ûĤÄÉÃ×ÄÒÅÝÖÆ±¸ºÍÓ¦ÓÃÆ½Ì¨£¬£¬£¬²¢¿ªÕ¹ÁËÆäÔÚÖ×Áö¾«×¼ÖÎÁÆÁìÓòµÄϵÁÐÓ¦ÓÃÑо¿£º£º1£©Éè¼ÆÍâòչʾBCMAµÄϸ°ûÍâÄÉÃ×ÄÒÅÝ£¬£¬£¬°ÐÏòÖкÍ΢ÇéÐÎÖйýÁ¿µÄ´Ù°©Òò×ÓAPRILÓëBAFF£¬£¬£¬Ôö½ø¶à·¢ÐÔ¹ÇËèÁö¶ÔÅðÌæ×ôÃ×µÄÃô¸ÐÐÔ£¬£¬£¬½µµÍÒ©ÎïµÄ¶¾¸±×÷Óà (Acta Biomater, 2022, IF=10.6)£» 2£©¹¹½¨±í´ïCD64µÄÄÉÃ×ÄÒÅÝżÁªPD-1¿¹Ì壬£¬£¬×èÖ¹Tϸ°ûºÄ½ß£¬£¬£¬ÔöÇ¿ÃâÒßÖÎÁÆÐ§¹û(Theranostics£¬£¬£¬2021£¬£¬£¬IF=11.6)£»3£©Éè¼Æ¸ºÔؼªÎ÷Ëû±õµÄ¹ý±í´ïPD-1µÄÄÉÃ×ÄÒÅÝ£¬£¬£¬ÏÔÖøÒÖÖÆÁËÈéÏÙ°©µÄÔöÖ³ (Pharmaceutics, 2022, IF=6.5)¡£ÕâЩÑо¿Ð§¹ûΪ»ùÓÚÖÎÁÆÐ°еãÀ´¿ª·¢°ÐÏòÒ©ÎïÒÔʵÏÖ¶àÖØÖÎÁÆÐ§Ó¦ÌṩÁËеÄÕ½ÂÔ¡£ 

ÂÛÎÄÁ´½Ó£º£º https://doi.org/10.1016/j.canlet.2024.216861

¡¾ÍøÕ¾µØÍ¼¡¿